Press Release|Articles|May 7, 2025
Camber Pharmaceuticals Announces Addition of Eslicarbazepine Acetate Tablets
Listen
0:00 / 0:00
Key Takeaways
- Eslicarbazepine Acetate Tablets target partial-onset seizures in patients aged four and older, broadening treatment options.
- Available strengths include 200 mg, 400 mg, and 800 mg in 30-count bottles, and 600 mg in a 60-count bottle.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Eslicarbazepine Acetate Tablets to its portfolio.
Eslicarbazepine Acetate Tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Eslicarbazepine Acetate Tablets are available in:
- 200 mg, 400 mg, and 800 mg strengths in 30-count bottles
- 600 mg strength in a 60-count bottle
To find out more information on Eslicarbazepine Acetate Tablets, please visit:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
2
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
3
Ribociclib Plus Fulvestrant Shows Strong PFS and OS Benefits in Patients With Invasive Lobular Carcinoma
4
FDA Approves First At-Home Treatment Device for Depression
5
